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Universite´ Paris 12, Faculte´ de Me´decine, Cre´teil F-94000, FranceProgression of chronic hepatitis is highly variable among individuals, as the result of several host, viral and environmen-
tal factors. The latter have been extensively investigated in order to ameliorate hepatitis C outcome, particularly in dif-
ﬁcult-to-treat patients. Over the last decade, several studies have shown that a combination of HCV infection and high
levels of alcohol abuse results in synergistic acceleration of liver ﬁbrogenesis. In addition, recent data indicate that light
alcohol intake may also exacerbate ﬁbrosis progression. It has also been suggested that cigarette smoking may enhance
activity grade in patients with chronic hepatitis C, thereby increasing progression of ﬁbrosis. This assumption mostly relies
on epidemiological evidences in the absence of pathogenic studies. Finally, cannabis use is increasingly emerging as a novel
co-morbidity in patients with chronic hepatitis C. Indeed, regular cannabis smoking is an independent predictor of both
ﬁbrosis and steatosis severity in infected patients. In addition, experimental studies have shown that cannabinoid CB1
receptors enhance liver ﬁbrogenesis and steatogenesis by distinct mechanisms, therefore strongly supporting epidemiolog-
ical ﬁndings. Altogether, patients should be informed of the deleterious impact of alcohol, tobacco and cannabis use and
should be oﬀered appropriate support to achieve abstinence.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Chronic hepatitis C (CHC) aﬀects over 170 million
people worldwide and is a leading cause of cirrhosis
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time, some individuals run a benign clinical course for
decades and others, rapidly progress to end-stage liver
disease. Several factors have been linked to ﬁbrosis pro-
gression (Table 1) or to a reduced rate of antiviral
response and among those, comorbidities amenable to
therapeutic intervention require special attention, par-
ticularly in diﬃcult-to-treat patients such as non-
responders to standard therapy. Not surprisingly,
coﬁbrogenic eﬀects of alcohol intake have been largely
described over the last decade. More recently, tobacco
use and cannabis use have emerged as novel cofactors
of ﬁbrosis enhancement in patients with CHC. The
scope of this paper is to review current data on the
impact of alcohol intake, tobacco and cannabis use on
CHC outcome.Published by Elsevier B.V. All rights reserved.
Table 1
Factors associated with ﬁbrosis progression in patients with chronic
hepatitis C
Host Older age at contamination
Male gender
Virus Duration of infection
Co-morbidities HIV co-infection
Immunosuppression
High BMI
Insulin resistance, diabetes
Environmental Alcohol intake
Cigarette smoking
Cannabis use
Others Fibrosis stage
Activity grade
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2.1. Epidemiological data
Deﬁning the impact of alcohol use on hepatitis C has
been the focus of intensive eﬀorts during the last decade,
given the frequent coexistence of alcoholism and HCV
infection [2]. Hence, the third US National Health and
Nutrition Examination Survey reported that 20% of
patients with CHC consume 2 or more drinks daily.
Similarly, HCV infection is highly prevalent among
alcohol abusers, with HCV antibody seroprevalence
ranging between 4.6 and 55.5% [2]. The reasons for these
high rates of HCV infection in alcohol abusers remain
unclear and may be related to both enhanced exposure
to HCV and decreased spontaneous viral clearance in
excessive drinkers. Although intravenous drug users
are frequently alcohol abusers [3], high rates of HCV
seropositivity have been found in alcohol users with
no identiﬁed risk for viral hepatitis [4], suggesting an
impact of alcohol on HCV persistence. This assumption
was recently supported in a study comparing two groups
of veterans with recovered or ongoing HCV infection.
By multivariate analysis, a history of past or present
alcohol abuse was signiﬁcantly associated with chronic
HCV infection [5].
2.2. Impact of alcohol on CHC outcome
Several lines of evidence indicate that alcohol aﬀects
survival of patients with CHC. In a study of a US
national sample of hospitalizations, alcohol abuse was
associated with a 40% increased odds of death in
patients with CHC [6]. In addition, retrospective analy-
sis of 6354 consecutive admissions related to alcohol
dependence or abuse in a single hospital found a trend
for an increased inpatient mortality in individuals with
HCV infection [7].An overwhelming number of studies have shown that
high levels of alcohol intake accelerate ﬁbrosis progres-
sion in patients with CHC. In a retrospective analysis of
1574 patients, Poynard et al. showed that heavy alcohol
consumption (P50 g/d) was an independent predictor
of ﬁbrosis progression rate [8]. Similarly, several reports
identiﬁed heavy alcohol intake (P50 g/d) as a major
cofactor of ﬁbrosis progression [8–12] or cirrhotic out-
come (Table 2) [9,12–21]. These studies were somewhat
limited by their predominant cross-sectional or retro-
spective design and displayed signiﬁcant variability in
the deﬁnition of alcohol abuse in terms of level, duration
and recording, but nevertheless yielded consistent
results. In addition, longitudinal follow-up of patients
with CHC also found that alcohol use predicts ﬁbrosis
progression [10], cirrhotic decompensation [18] and
increases the rate of liver-related deaths [20]. Finally, a
recent meta-analysis comprising 15 positive and 5 nega-
tive studies in a total of 13,706 patients estimated the
pooled relative risk of cirrhosis or decompensated cir-
rhosis in alcohol abusers to be 2.33 (95% CI 1.67–
3.26) [22].
Fewer studies have evaluated the impact of low to
moderate alcohol intake on ﬁbrosis progression
[9,11,18,23,24]. Hezode et al. prospectively evaluated
predictors of clinically signiﬁcant ﬁbrosis (PF2 accord-
ing to the Metavir scoring system) in 260 patients with a
daily alcohol intake 650 g during the 6 months preced-
ing liver biopsy [24]. By multivariate analysis, daily alco-
hol consumption ranging between 31 and 50 g was a
strong predictor of ﬁbrosis stage PF2 (OR = 4.3; CI:
1.2–16.0). A retrospective analysis of 78 patients with
paired biopsies and a daily alcohol consumption below
40 g found that progression of ﬁbrosis was associated
with a higher drinking frequency and a higher level of
alcohol intake per occasion [11]. Alcohol intake below
30 g/day was speciﬁcally investigated in two studies that
found a non signiﬁcant trend for worsening of liver
ﬁbrosis [18,20]. Finally, Monto et al. analysed the aver-
age lifetime alcohol intake in 800 HCV patients and
found a stepwise increase in mean ﬁbrosis stage between
non-drinkers, light (620 g), moderate (>20–50 g) and
heavy (P50 g) drinkers, although diﬀerences did not
reach statistical signiﬁcance [23]. Overall, these results
suggest that there is no safe level of alcohol intake.
2.3. Impact of alcohol on treatment outcome
Past and ongoing alcohol abuse has been reported to
dose-dependently decrease the response to standard
interferon treatment [2]. However, studies were fraught
with several limitations such as the low number of
patients included, the retrospective design or the use of
standard interferon monotherapy. Nevertheless, these
observations suggested that alcohol might reduce sensi-
tivity to interferon and/or adherence to treatment. These
Table 2
Impact of alcohol on progression to cirrhosis in patients with chronic hepatitis C
Author, country, year Patients (% cirrhosis) Deﬁnition of alcohol
intake
Impact of alcohol on
cirrhotic outcome
Other cofactors of
ﬁbrosis
Roudot-Thoraval,
France, 1997 [12]
5789 CHC (21%) >50 g/d (F), >60 g/d
(M), at least 1 year
OR = 3.38 (2.82–4.05) Age, route of
transmission, duration
of infection, HBV
coinfection
Wiley, US, 1998 [15] 176 CHC (39%) >40 g/d (F), >60 g/d
(M), at least 5 years
Higher rate of cirrhosis:
58% vs 10% in the 2nd
decade of the disease
(p < 0.01)
–
Ostapowicz, Australia,
1998 [9]
234 CHC (21%) Per 100.000 g lifetime
intake
OR = 1.16 (1.02–1.31) Age
Pol, France, 1998 [19] 553 CHC (12.5%) >80 g/d at least 2 years RR = 2.9 (1.6–5.4) Age at contamiantion,
duration of infection,
HIV status
Corrao, Italy, 1998 [14] 285 cirrhosis quantitative lifetime: 0,
25, 50, 75, 100,P125 g/d
Additive for >50 g/d
alcohol
Age, gender
417 controls with acute
diseases
Synergistic for alcohol
>125 g/d
Bellentani, Italy, 1999
[21]
General population
survey
<30 g/d for 10 years NS Male gender, age,
genotype 1b
162 HCV (12%) >30 g/d for 10 years OR = 3.8 (1.2–7.4)
Thomas, US, 2000 [18] Follow-up of 1667 IDU
with CHC (2.3%)
cirrhosis at 8.8 years
90–260 g/week at entry RR = 1.57 (0.65–3.79) Age at enrollment
>260 g/week at entry RR = 3.6 ( 1.73–7.52)
Harris, US, 2001 [13] Follow-up of post
transfusion cohort; 206
CHC (17.0%) and 535
controls (3.2%)
>80 g/d OR = 4.0 (2.1–7.7) –
Harris, UK, 2002 [20] Follow-up of post
transfusion cohort; 924
CHC vs 475 controls
(9.5%)
>260 g/week RR = 2.84 (1. 09–7.41) Male gender
Delarocque, 2005 [17] 3404 VHC; ﬁrst referral
in 26 French reference
centers (11.5%)
>30 g/d (F), >40 g/d (M) 2.6 (1.9–3.5) Male gender, age >39 at
referral, HIV, duration,
ag HB status, risk
factors,
Stroﬀolini, 2006 [16] 5632 CHC referred to 79
italian hospitals (18.9%)
10–40 g/d 0.8 (0.4–1.4) Age, gender
P 40/d 2.2 (1.3–4.0)
IDU, intravenous drug user; RR, risk ratio; OR, odds ratio.
A. Mallat et al. / Journal of Hepatology 48 (2008) 657–665 659issues were addressed in a prospective multicenter study
of 726 patients receiving a combination of standard
interferon and weight-based ribavirin [25]. Adherence
to treatment and sustained viral response rates were sim-
ilar in non-drinkers and past alcohol users, as deﬁned by
abstinence within the year preceding treatment. In con-
trast, recent alcohol use was associated with a signiﬁcant
increase in treatment discontinuation rate (40% vs 26%)
and a corresponding reduction in sustained viral
response (14% vs 20%). Subgroup analysis excluding
patients with early drop-out indicated that the rate of
viral eradication was similar in alcohol users undergoing
a full course of treatment, compared to non-drinkers.
These results strongly suggest that alcohol reduces ther-
apeutic response by decreasing patient adherence rather
than by reducing sensitivity to interferon. Therefore,
alcohol users should not be deferred from treatmentbut should rather be oﬀered speciﬁc support to achieve
abstinence and improve adherence. In this respect, it
has been suggested that detoxiﬁcation programs might
be more successful in alcohol abusers with concurrent
HCV infection compared to excessive drinkers without
HCV infection [26].
2.4. Molecular mechanisms of interactions between
alcohol and HCV
Despite strong epidemiological evidence linking alco-
hol use to acceleration of liver injury in CHC, little is
known about the combined eﬀects of ethanol and
HCV on the pathogenesis of liver disease. Proposed
mechanisms of interaction include enhancement of viral
replication, increased oxidative stress and cytotoxicity,
as well as impairment of immune response.
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viral load in alcohol abusers compared to non-drinkers
[2], suggesting that alcohol may enhance viral replica-
tion. In support of this assumption, alcohol metabolites
were shown to potentiate expression of viral proteins in
an experimental replicon system [27]. However, other
studies failed to demonstrate an impact of alcohol on
serum HCV titers [2] and a recent meta-analysis from
9 available studies concluded that there were no signiﬁ-
cant diﬀerences in serum HCV viral titers of alcohol
abusers and non-drinkers [25].
Both HCV and alcohol are known stimuli of hepatic
oxidative stress and lipid peroxidation, suggesting that
coexistence of these factors might enhance these path-
ways [28], thereby leading to increased activation of liver
ﬁbrogenic cells and subsequent acceleration of ﬁbrogen-
esis. Thus, chronic administration of alcohol to HCV-
core transgenic mice results in additive hepatic lipid per-
oxidation, synergistic induction of the proﬁbrogenic
cytokine TGF-b1 and activation of hepatic stellate cells
[29]. In addition, indirect clinical evidence suggests that
enhanced oxidative stress may contribute to increased
severity of CHC in alcohol users: in a series of 145
patients with CHC, the frequency of serum antibodies
to lipid peroxide adducts was signiﬁcantly increased in
alcohol users compared to non users. Moreover, there
was a signiﬁcant correlation between the titers of lipid-
peroxidation related antibodies and the severity of
inﬂammation and ﬁbrosis [30].
Experimental data suggest that alcohol-induced
impairment of immunity may account for the high rates
of persistent viral infection reported in excessive drink-
ers [5]. Mice chronically exposed to ethanol show a
reduced cellular immune response to HCV core and
non structural proteins, following alteration in dendritic
cell maturation leading to a propensity to generate Th2-
immune response [31]. In keeping with these data, plas-
macytoid and myeloid dendritic cells of patients with
CHC display a reduced allostimulatory potential which
is further impaired in the presence of alcohol [32].
2.5. Summary
Coexistence of HCV infection and alcohol intake is a
frequent ﬁnding. Assessment of the interaction between
alcohol and HCV is inherently diﬃcult, due to the inac-
curacy in alcohol consumption recording. Nonetheless,
available studies indicate that alcohol intake is a cofac-
tor of worsened outcome and no safe threshold may be
deﬁned at the present time.3. Impact of cigarette smoking on the course of CHC
Whereas morbidity and mortality of cardiopulmo-
nary diseases associated to tobacco use have been exten-sively documented, available clinical evidence suggests
that cigarette smoking does not induce chronic liver
injury in healthy individuals. Likewise, experimental
data documenting hepatotoxicity and/or liver-directed
ﬁbrogenic eﬀects of tobacco components are scarce [33].
That tobacco use might negatively impact chronic
liver injury was initially suggested by two retrospective
studies indicating a deleterious eﬀect of cigarette smok-
ing on prevalence and/or severity of alcoholic [34] and
HBV-related cirrhosis [35]. More recently, a history of
smoking has been incriminated as a predisposing cofac-
tor of primary biliary cirrhosis [36]. Moreover, tobacco
use was identiﬁed as an independent predictor of
advanced ﬁbrosis at presentation in a retrospective
study of patients with primary biliary cirrhosis [37].
Finally, several reports suggest that cigarette smoking
is associated with an increased incidence of hepatocellu-
lar carcinoma associated with cirrhosis [35,38–42].
Table 3 summarizes the main data regarding the
impact of cigarette smoking on ﬁbrosis progression in
CHC. Two retrospective studies showed that tobacco
use was an independent predictor of ﬁbrosis stage
[43,44]. However, in the study of Pessione et al., further
investigation indicated that this relationship was lost
when activity grade was included in the multivariate
analysis, suggesting that cigarette smoking may indi-
rectly enhance ﬁbrosis severity, by increasing necroin-
ﬂammatory grade [43]. Hezode et al. subsequently
investigated this hypothesis in a prospective study and
found that recent tobacco use predicted activity grade,
irrespective of alcohol intake [45]; in contrast, whereas
activity grade was an independent cofactor of ﬁbrosis
severity, there was no relationship between tobacco
use and ﬁbrosis stage by multivariate analysis [45]. The
impact of tobacco use was also investigated in a large-
scale population study, using ALT levels as a surrogate
marker of necroinﬂammation. In this survey of 886
patients with positive HCV antibodies, alcohol intake
and cigarette smoking were independent predictors of
elevated alanine aminotransferase levels [46]. Alto-
gether, these data suggest that cigarette smoking may
aggravate necroinﬂammation associated with CHC
and thereby accelerate ﬁbrogenesis.
Pathways underlying cigarette smoking induced pro-
gression of CHC or other chronic liver diseases remain
elusive in the absence of experimental data. Studies in
other tissues indicate that tobacco use enhances several
pathways of the wound healing response, such as oxi-
dative stress [47,48] or the production of proinﬂamma-
tory cytokines [49], leading to accumulation of
ﬁbrogenic cells and enhancement of extracellular
matrix protein synthesis [47]. Moreover, nicotine has
also been shown to impair immune response [50].
Finally, tobacco use also generates insulin resistance
[51,52], a known cofactor of ﬁbrosis severity during
CHC [53,54].
Table 3
Impact of tobacco smoking on severity of CHC
Authors, year P/R Patients (n) Deﬁnition of
tobacco use
Impact on ALT
level elevationa
Impact on activity
gradea
Impact on ﬁbrosis
stagea
Other independent
cofactors
of ﬁbrosisa
Pessione, 2001 [43] R 310 None – Increase in mean OR = 1 Age at biopsy
615 pack-years activity grade OR = 1.2 (0.6–2.2)b Male gender
>15 pack-years P = 0.04 OR = 1.9 (1.1–3.6)b Alcohol intake
>40 g/d
Wang, 2002 [46] P 880 Yes vs No OR = 1.8
(1.1–2.7)
– – Frequent alcohol
use Age >50
Hezode, 2003 [45] P 244 None – OR = 1 NS Age at biopsy
615 cig/day OR = 1.2 (0.5–2.8) Male gender
>15 cig/day OR = 3.6 (1.5–8.8) Alcohol intake
>30 g/d
Necroinﬂammatory
grade
Dev, 2006 [44] R 170 Number of cigarettes
smoked/day at
presentation
– – OR = 1.3 (1.0–1.8)c HCV genotype 1,
Serum VEGF-D
P, prospective; R, retrospective; NS, not signiﬁcant.
a By multivariate analysis.
b Only if necroinﬂammatory grade omitted in the model.
c No data on necroinﬂammatory grade.
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spective, suggest that cigarette smoking may enhance
necroinﬂammation in patients with CHC, thereby accel-
erating progression of ﬁbrosis. Additional prospective
investigations are warranted in order to conﬁrm these
observations and experimental studies are needed to
support these ﬁndings.4. Cannabis and the endocannabinoid system
Cannabis Sativa has been used for medicinal purposes
over millennia. During the 19th century, the plant was
increasingly recommended for its analgesic, muscle
relaxant, orexigenic and anticonvulsant properties in a
variety of diseases, ranging from epilepsy, tetanus, rheu-
matism to gastroenterological symptoms, until growing
concern about the dangers of abuse led to banning from
the pharmacopeia in the 1930’s [55–57]. Recreational use
of marijuana progressively expanded worldwide thereaf-
ter. Albeit cannabis use primarily occurs in teenagers
and young adults and is usually self-limited, continued
consumption for prolonged periods has been described,
predominantly in frequent users [58,59].
4.1. Cannabis and the endocannabinoid system
D9-tetrahydrocannabinol (THC) was identiﬁed in
1964 as the compound responsible for psychoactive
eﬀects of cannabis, and further studies revealed the con-
current presence of over 60 bioactive phytocannabinoids
[55–57,60]. Subsequent research eﬀorts led to the charac-
terisation of a cannabinoid system, comprising speciﬁcbinding sites (CB1 and CB2), their endogenous lipid
ligands known as endocannabinoids, and a machinery
dedicated to endocannabinoid and synthesis and degra-
dation [55,57,60,61].
CB1 and CB2 belong to the superfamily of G-protein
coupled receptors and display similar aﬃnity for THC
[57,60–62]. CB1 receptor is highly expressed in the cen-
tral nervous system and accounts for the psychoactive
eﬀects of cannabis [55,57,62]. CB2 receptor displays
lower levels of expression and is primarily found in
immune cells [57,61]. Anandamide and 2-arachidonoyl-
glycerol are currently the best known endocannabinoids.
[62,63]. Both compounds derive from membrane fatty
acids on demand and undergo intracellular uptake and
degradation by speciﬁc pathways, following receptor
binding. Anandamide preferentially binds CB1 recep-
tors, whereas 2-arachidonoylglycerol displays similar
aﬃnity for CB1 and CB2 receptors [56,57].
4.2. Cannabinoids and liver ﬁbrogenesis: experimental
data
Over the last decade, accumulating reports have
shown that distribution of CB1 and CB2 receptors is
far less restricted than initially thought and accordingly,
the cannabinoid system has been implicated in a wide
variety of physiological and pathological conditions
[56,57]. We recently showed that CB1 and CB2 receptors
are highly upregulated in cirrhotic human surgical liver
samples, predominating in liver ﬁbrogenic cells [64,65].
Moreover, marked elevations in circulating levels of
anandamide and hepatic concentrations of 2-AG were
described in cirrhotic patients and in rodent models of
Table 4
Factors independently related to rapid ﬁbrosis progression ratea in 267
patients with untreated CHC of known duration (from [70])
FPR > 0.074
U/year (%)
OR 95% CI p
Disease-time cannabis use
None 39.7 1
Occasional 42.5 1.3 0.5–3.3 0.57
Daily 68.5 3.4 1.5–7.4 0.005
Age at contamination
620 years 41.4 1
21–40 years 52.9 2.4 1.2–4.8 0.01
>40 years 70 10.5 3.0–37.1 <0.001
Metavir activity grade
<A2 25.9 1
PA2 67.5 5.4 2.9–10.3 <0.001
HCV genotype
1 42.0 1
2 35.0 1.0 0.3–3.1 0.95
3 74.2 3.4 1.5–7.7 0.005
4/5 45.8 1.2 0.4–3.6 0.69
Disease-time alcohol intake
<30 g/day 42.1 1 1
P30 g/day 69.3 2.2 1.1–4.5 0.03
Steatosis
Absent-mild 40.7 1
Moderate-severe 72.4 2.0 1.0–4.1 0.05
a As deﬁned by ﬁbrosis progression rate >0.076 Metavir U/year
(median value of the cohort).
Daily cannabis use
CCl4, TAA,
Bile duct ligation
High fat diet
fa/fa mice
Endocannabinoids:
Experimental data
Cannabis and
chronic hepatitis C
Fibrosis
Steatosis
CCl4
High fat diet
ob/ob mice
Liver fibrosis Steatosis
Fig. 1. Cannabis and chronic hepatitis C: impact and experimental
mechanisms CCl4, carbon tetrachloride; TAA, thioacetamide. [This ﬁgure
appears in colour on the web].
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role of the endocannabinoid system during chronic liver
disease. We therefore delineated the respective roles of
CB1 and CB2 receptors in liver ﬁbrogenesis, owing to
the use of mice genetically deﬁcient for CB1 or CB2
receptors or treated with the CB1 antagonist
rimonabant.
CB1 receptors were identiﬁed as potent enhancers of
liver ﬁbrogenesis, based on the ﬁnding that administra-
tion of the CB1 antagonist rimonabant or genetic inac-
tivation of CB1 receptors reduces the density of liver
ﬁbrogenic cells and inhibits ﬁbrosis progression in three
models of chronic liver injury (carbon tetrachloride, thi-
oacetamide or bile duct ligation) [65]. In addition, cul-
ture studies demonstrated that CB1 enhances
proliferation of liver ﬁbrogenic cells and and enhances
their survival [65]. Similar ﬁndings were subsequently
reported by others in mice treated with the CB1 antag-
onist AM 251 [69]. In contrast, experiments in CB2
KO mice chronically exposed to carbon-tetrachloride
indicated that CB2 receptors exert antiﬁbrogenic prop-
erties, related to enhanced apoptosis and reduced prolif-
eration of hepatic myoﬁbroblasts [64]. In aggregate,
these ﬁndings revealed opposite eﬀects of CB1 and
CB2 receptors on liver ﬁbrogenesis and suggested that
cannabis use may alter ﬁbrosis progression in patients
with ongoing chronic liver injury.4.3. Impact of cannabis use on ﬁbrosis severity during
CHC
We therefore investigated the impact of cannabis
smoking on ﬁbrosis severity in a cross-sectional study
of 270 patients with untreated CHC of known duration
[70]. Data were recorded at the time of liver biopsy,
including epidemiological details, lifetime histories of
alcohol, tobacco and cannabis use, body mass index,
metabolic parameters and viral genotype. Patients were
categorized according to cannabis smoking over the
span of HCV disease as nonusers, occasional (<1 joint
weekly) or daily users (at least 1 daily joint during the
course of the disease). Logistic regression analysis iden-
tiﬁed daily cannabis use as a strong predictor of the
severity of liver ﬁbrosis, as assessed by ﬁbrosis stage or
ﬁbrosis progression rate (Table 4). A subsequent inde-
pendent study reported similar ﬁndings [71], supporting
our recommendation that patients with ongoing CHC
should abstain from regular cannabis use.
4.4. Cannabis and steatosis in patients with chronic
hepatitis C
Steatosis, a common histologic ﬁnding in patients
with CHC, is associated with higher rates of ﬁbrosis pro-
gression and decreased sensitivity to antiviral treatment
[53,54,70,72]. Factors contributing to steatogenesis dur-
ing CHC include HCV genotype 3, the presence of a
metabolic syndrome and alcohol abuse [73,74].
Recent experimental studies suggest a central role of
CB1 and CB2 receptors in the pathogenesis of metabolic
steatosis (Fig. 1). Osei Hyiaman et al. revealed an
increased CB1-dependent cannabinoid tone in the liver
and the hypothalamus of obese mice with fatty liver
and demonstrated that CB1 receptors promote liver ste-
atogenesis via central orexigenic properties and periphe-
ral lipogenic eﬀects in hepatocytes [75]. In line with these
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onist rimonabant to genetically obese fa/fa rats pre-
vented the development of steatosis and improved
parameters of the metabolic syndrome [76]. We recently
investigated the impact of CB2 receptors on metabolic
steatosis in CB2KO mice submitted to a high fat diet
and showed that CB2 receptors promote steatosis, by
enhancing inﬂammation in the adipose tissue (prelimin-
ary results, [77]).
Collectively, these data identify CB1 and CB2 recep-
tors as key players in metabolic steatogenesis and sug-
gest that the cannabinoid system may play a signiﬁcant
role in the development of steatosis associated to
CHC. We therefore took advantage of the high preva-
lence of steatosis in patients with chronic hepatitis C,
and investigated the impact of recent (6 months) can-
nabis use on the severity of steatosis in 277 untreated
patients. By logistic regression analysis, daily cannabis
use was identiﬁed as a predictor of severe steatosis,
irrespective of genotype, activity grade, body mass
index, the presence of diabetes or viral load (Fig. 1)
[78].
4.5. Future prospects
Altogether, our results indicate that regular cannabis
use is strongly associated with enhanced steatosis and
worsening of ﬁbrosis in patients with CHC. These ﬁnd-
ings are supported by our experimental studies demon-
strating that CB1 receptors promote liver ﬁbrogenesis
and steatosis and that CB2 receptors display antiﬁbro-
genic eﬀects and enhance steatosis (Fig. 1). We therefore
recommend that management of patients with CHC
should routinely include evaluation of cannabis use his-
tory and incentive to abstain from continued consump-
tion. Whether the deleterious impact of cannabis use
also holds true in other chronic liver diseases remains
to be investigated.
Rimonabant, the ﬁrst generation of CB1 antagonists,
has been approved by the European Agency for the
Evaluation of Medicinal products in 2006 for the treat-
ment of obesity/overweight and associated cardio-meta-
bolic risk factors, and other CB1 antagonists are
undergoing clinical development [79]. Therefore, the
identiﬁcation of proﬁbrogenic and steatogenic proper-
ties of CB1 receptors might ﬁnd therapeutic applications
for patients with CHC in the coming years. Future clin-
ical trials should evaluate the antiﬁbrosing properties of
CB1 antagonists in patients with advanced ﬁbrosis, non-
responders to antiviral therapy, or in patients with a
contraindication to ribavirin or interferon. CB1 antago-
nism might also open a new therapeutic approach in the
management of insulin resistance associated to chronic
hepatitis C. Indeed, recent data indicate that insulin
resistance reduces sensitivity to interferon-based treat-
ment and clinical trials are under way in order to evalu-ate the impact of insulin-sensitizers on the rate of viral
eradication following combined antiviral therapy [80].5. Conclusion
Physicians are largely aware of the deleterious eﬀects of
alcohol abuse in patients with chronic hepatitis C. Recent
data suggest that there is no safe level of alcohol intake in
this setting, and that abstinence should be recommended.
In addition, abstinence appears to enhance the rate of
antiviral response. Accordingly, patients should be
oﬀered appropriate support, including deaddiction pro-
grams if needed. Awareness of the harmful eﬀects of
tobacco and cannabis use on ﬁbrosis progression is more
recent. Additional studies should further document the
impact of tobacco. Evaluation of cannabis exposure
should be part of the routine evaluation of patients with
chronic hepatitis C and patients should strongly be
advised to refrain from regularly using cannabis.References
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